Hancock Jaffe Mourns the Loss of Director Marc Robins

Jaffe Mourns the Loss of Director Marc Robins

California., April 30, 2019 - Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices

that restore cardiac and vascular health, announces the passing of its director, Marc Robins. Mr. Robins passed away from complications

from chronic venous insufficiency.

Berman, Hancock Jaffe's Chief Executive Officer stated, "It is ironic that Marc lost his life to the same disease

that our VenoValve is being developed to address. Marc was a big proponent of Hancock Jaffe and his unwavering support and sense

of humor will be greatly missed. We will continue the fight against chronic venous insufficiency in Marc's honor and we

send our deepest sympathies to Marc's wife Barbara and his entire family."

Venous Insufficiency (CVI) of the deep vein system is a condition that occurs when the valves in the veins of the venous system

of the leg are injured or destroyed, causing blood to flow backwards (reflux) and pool in the lower extremities, and resulting

in increased venous pressure (venous hypertension). Severe CVI often results in significant disability which includes swelling,

intense pain, and skin ulcerations that become ongoing, open wounds. Approximately 2.6 million patients in the U.S. suffer from

CVI due to reflux in the deep venous system, and there are currently no FDA approved treatments for the condition.

Robins was one of Hancock Jaffe's three independent directors. A memorial service for Mr. Robins is planned for Saturday,

May 18, 2019 from 2:00 to 5:00 p.m. Pacific time at Trinity Lutheran Church, 5520 NE Killingsworth, Portland, Oregon.

W. Robins, CFA was an experienced fund manager, publisher and equity analyst. Most recently, he was the fund manager at Crown

Capital Management LP, a new micro-cap and small-cap fund he started in July 2018. Since 2003, Mr. Robins founded and has been

a registered investment advisor at Catalyst Financial Resources LLC, a provider of institutional level research for micro-cap

companies. Catalyst Financial is the follow-on to The Red Chip Review, which Mr. Robins launched in 1993. At its peak, Red Chip

provided research coverage on over 500 companies and had a subscriber base of over 7,000 investors, 100 brokerage offices and

25 money managers. Red Chip was sold in 2002. In addition to Red Chip, Mr. Robins has been published in numerous national publications

including The Wall Street Journal, Bloomberg, Investor's Business Daily, Kiplinger's, and Forbes, where he had his

own column for 8 years. For more information on Marc Robins, please click here.

Hancock Jaffe Laboratories, Inc.

Jaffe Laboratories (NASDAQ: HJLI) specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to

establish improved standards of care for treating cardiac and vascular diseases. Hancock Jaffe currently has two lead product

candidates: the VenoValve , a porcine based valve which is intended to be surgically implanted in the deep venous system of

the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraft , a bovine tissue based off the

shelf conduit intended to be used for coronary artery bypass surgery. Hancock Jaffe has a third product candidate, which is a

porcine tissue-based heart valve, which may be a candidate for pediatric aortic/mitral valve replacement. Hancock Jaffe has a

19-year history of developing and producing FDA approved medical devices that sustain or support life. The current management

team at Hancock Jaffe has been associated with over 80 FDA or CE marked medical devices. For more information, please visit HancockJaffe.com.

Note on Forward-Looking Statements

press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories,

Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant

risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects,"

"may," "will," "could," "would," "should," "believes,"

"expects," "anticipates," "estimates," "intends," "plans," "potential"

or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management

and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities

and Exchange Commission. Actual results (including, without limitation, the performance of the new board members described herein)

may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve

certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's

control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information,

future presentations or otherwise, except as required by applicable law.

& Investor Relations Contact: